Ontology highlight
ABSTRACT:
SUBMITTER: Flinn IW
PROVIDER: S-EPMC6220789 | biostudies-literature | 2018 Nov
REPOSITORIES: biostudies-literature
Flinn Ian W IW Patel Manish M Oki Yasuhiro Y Horwitz Steven S Foss Francine F FF Allen Kerstin K Douglas Mark M Stern Howard H Sweeney Jennifer J Kharidia Jahnavi J Kelly Patrick P Kelly Virginia M VM Kahl Brad B
American journal of hematology 20180831 11
Duvelisib (IPI-145) is an oral dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ in clinical development for the treatment of hematologic malignancies, including indolent non-Hodgkin lymphoma (iNHL). In a Phase 1, open-label study to determine the maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, clinical activity, and safety of duvelisib monotherapy in patients with advanced hematologic malignancies, duvelisib was administered at eight dose levels (8-100 mg BID) in a d ...[more]